Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXHALE-5
2024-510810-33-00Phase 3Unknown
- Sponsor
- Areteia Therapeutics
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 29
01
Overview
Phase 3, open-label, single-arm trial of dexpramipexole in eosinophilic asthma (EA), sponsored by Areteia Therapeutics. Primary endpoint: Treatment-emergent adverse events, clinical laboratory parameters, vital signs, and 12-lead ECGs. Status: unknown.
02
Drugs
dexpramipexole
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2024-510810-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510810-33-00.